LEO Pharma presented data at the 33rd European Academy of Dermatology and Venereology (EADV) Congress on the effectiveness and safety of delgocitinib cream for moderate to severe chronic hand eczema (CHE).
The DELTA FORCE trial, a 12-week phase 3 study, compared delgocitinib cream to oral alitretinoin capsules. Delgocitinib cream showed superior efficacy, with a greater reduction in Hand Eczema Severity Index (HECSI) score than alitretinoin. It also achieved higher rates of Investigator’s Global Assessment (IGA)-CHE treatment success.
In addition to DELTA FORCE, other research presented at EADV included an analysis of 638 patients treated with delgocitinib cream across multiple clinical trials. The analysis demonstrated the drug’s effectiveness across five CHE subtypes: irritant contact dermatitis, vesicular hand eczema, allergic contact dermatitis, atopic hand eczema, and hyperkeratotic hand eczema.
Findings from the RWEAL study, which involved 1939 CHE patients, highlighted the diverse nature of the condition, with patients often presenting with multiple subtypes.
Delgocitinib cream, if approved, would provide a topical alternative to alitretinoin for severe CHE patients who do not respond adequately to topical corticosteroids. It has demonstrated promising results in both clinical trials and real-world settings, addressing an unmet need in CHE treatment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
